Heart Disease News and Research

Latest Heart Disease News and Research

Ground Zero Pharmaceuticals opens new office in Brisbane

A major increase in innovative concepts for exciting therapeutic and preventive new products in Australia has led to an expansion of GZP's activities Down Under, to better support clients in their efforts to take their programs to the US Food and Drug Administration.

6 Oct 2009

Triage NGAL Test allows early identification of AKI in ICU patients

According to a new study now available online, and to be published in an upcoming issue of the Journal of Critical Care, bedside testing for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) in patients being admitted to the intensive care unit can help to identify patients at risk for acute kidney injury (AKI).

6 Oct 2009

First Edition: October 6, 2009

Kathy Young, the veteran benefits administrator for a large plumbing supply company headquartered in Madison, Wis., is well versed in the often fiendish complexities of medical bills (Kaiser Health News and The Washington Post).

6 Oct 2009

HeartWare International receives approval to expand its clinical sites

HeartWare International, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to expand the number of clinical sites participating in its U.S. bridge-to-transplant trial, known as the ADVANCE trial.

6 Oct 2009

Tips for running a marathon

With 120,000 runners recently finding out whether they have successfully got a ballot place in the 2010 Virgin London Marathon, a buzz of activity is surrounding next year's iconic race.

6 Oct 2009

AAOS to participate in "Get Connected" electronic prescribing program

The American Academy of Orthopaedic Surgeons (AAOS) today announced their participation in "Get Connected," a program designed to help more of the nation's physicians and other prescribers use electronic prescribing.

6 Oct 2009

Cardiovascular Systems to build new manufacturing facility in Texas

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas.

6 Oct 2009

Gene therapy to improve ailing heart's contractions of muscle cells

Scientists from the Universities of Michigan and Minnesota show in a research report published online in the FASEB Journal (http://www.fasebj.org) that gene therapy may be used to improve an ailing heart's ability to contract properly. In addition to showing gene therapy's potential for reversing the course of heart failure, it also offers a tantalizing glimpse of a day when "closed heart surgery" via gene therapy is as commonly prescribed as today's cocktail of drugs.

6 Oct 2009

Hypertrophic Cardiomyopathy causes sudden cardiac death in children and young adults

Since Congress declared October “National Sudden Cardiac Arrest Awareness Month” one year ago, more than 250,000 Americans have suffered SCA. For too many, the underlying cause was Hypertrophic Cardiomyopathy (HCM), an inherited disease that affects one out of 500 Americans. What makes it all the more troubling is that early diagnosis of HCM through simple and inexpensive screening can reduce the risk of sudden cardiac death.

6 Oct 2009

Direct Flow Medical releases clinical results of its new Percutaneous Aortic Valve System

Direct Flow Medical, Inc., www.directflowmedical.com, released its 12 month data from the initial clinical trial for a new device to treat valve disease without invasive thoracic surgery. Direct Flow Medical is a privately held, emerging medical device company developing a next-generation, catheter based, percutaneous delivered prosthetic aortic valve.

6 Oct 2009

Boston Scientific begins patient enrollments for MADIT-RIT clinical trial

Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.

6 Oct 2009

New institutional advertising campaign based on real stories

NYU Langone Medical Center will launch a new institutional advertising campaign based on real stories from the Medical Center beginning on October 5, 2009. The campaign, “Any Given Moment,” captures and conveys some of the most powerful, intimate and uniquely human experiences to emerge from the Medical Center and features the Medical Center’s core clinical care and research strengths.

6 Oct 2009

Individuals who follow the Mediterranean dietary pattern at reduced risk to develop depression: Study

Individuals who follow the Mediterranean dietary pattern—rich in vegetables, fruits, nuts, whole grains and fish—appear less likely to develop depression, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Oct 2009

Framingham Heart Study receives $1M grant from the National Heart, Lung, and Blood Institute

Boston University School of Medicine's (BUSM) Framingham Heart Study (FHS) has received a two-year $1M challenge grant from the National Heart, Lung, and Blood Institute.

6 Oct 2009

Summa Health System to implement ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Summa Health System has selected ProVation® MD software for Cardiology procedure documentation and coding.

6 Oct 2009

Winner of 2009 NAMS award

Michael Holick, PhD, MD, director of the Bone Healthcare Clinic and the Vitamin D, Skin and Bone Research Laboratory at Boston University School of Medicine BUSM recently received the 2009 NAMS/Upsher-Smith Laboratories, Inc.Vitamin D Research Award from the North American Menopause Society (NAMS).

6 Oct 2009

Alcohol-impaired drivers account for higher emergency department costs

The costs of drinking and driving are all too apparent, with alcohol involved in 41 percent of all motor vehicle crash fatalities in 2006. In addition to the mortality and morbidity associated with drinking and driving, the economic impact of alcohol impaired driving is considerable, estimated at $51 billion, with medical costs accounting for 15 percent of that figure.

6 Oct 2009

Sit-and-reach test to gauge age-related arterial stiffness

How far you can reach beyond your toes from a sitting position - normally used to define the flexibility of a person's body - may be an indicator of how stiff your arteries are.

6 Oct 2009

Molecular biologist receives 2009 Nobel Prize in Physiology or Medicine

Molecular biologist Elizabeth H. Blackburn, PhD, 60, of the University of California, San Francisco, today was named to receive the 2009 Nobel Prize in Physiology or Medicine.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009